Decay of HIV-1 Reservoirs in Subjects on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

 

Brief Description:

AHRC (pronounced “ARC”) is a study of differences and changes over time in HIV reservoirs (groups of HIV-infected cells that ’hide’ from anti-HIV medications). This study enrolls people into one of six groups, based on their different treatment histories. Only Group 6, which will enroll up to 25 people who acquired or are suspected to have acquired HIV while taking long-acting cabotegravir (LA CAB) for pre-exposure prophylaxis (PrEP), is open under this version of the study. Participants will attend visits
every 12 weeks for the first 6 months on study, and then every 24 weeks, for a total time on study of approximately 6.5 years. At these visits, blood and a small amount of hair (if feasible) will be collected from all participants.


Purpose of this Study: This study is being done to try to answer questions about the ways that HIV infection is controlled, and if there are differences in the size of the reservoir of HIV in people who acquire HIV while on LA CAB compared to other situations. This may additionally have to do with a person’s viral load and CD4 count, when they started their anti-HIV medications, and genetic factors. 


Requirements to Enter Study (things that must be true for you):

  • Living with HIV or with blood tests strongly suggesting HIV
  • ≥ 18 years old
  • Receipt of long acting Cabotegravir injection within 90 days before collection of the blood sample of 1st reactive HIV test

Exclusion Criteria (things that cannot be true about you):

  • Have ever had an HIV viral load > 1500 copies/mL
  • Active Hepatitis B or C infection
  • Have an autoimmune disorder or condition requiring steroid therapy
  • Since suspected HIV diagnosis, have received any agent that is designed to affect the HIV reservoir
  • (e.g., latency-reversing agent, broadly neutralizing antibodies)
  • Talk to your study staff for a complete list of inclusion/exclusion criteria.
     

Treatment: Anti-HIV medications will not be supplied through this study.
 

Duration of Study: You will be expected to stay in the study for about 6.5 years.
 

Contact information:  

Clinical Research Coordinator: Audrey Soohoo  

Email: audrey.soohoo@ucsf.edu  

Phone number: 415-806-8554